生物制药公司PTC Therapeutics的高管最近出售了部分股票. Executives at PTC Therapeutics, a biopharmaceutical company, recently sold off portions of their stock.

PTC治疗公司的若干内部人员,包括CEO和CAO,最近出售了该公司股票的股份。 Several insiders at PTC Therapeutics, including the CEO and CAO, recently sold shares of the company's stock. 这些交易反映其所有权股份的不同减少。 These transactions reflect varying decreases in their ownership stakes. PTC 生物制药公司PTC Petrocuretics, 专注于罕见的病症,如Duchenne肌肉萎缩症和脊椎肌肉萎缩症。 PTC Therapeutics, a biopharmaceutical firm, focuses on rare disorders like Duchenne muscular dystrophy and spinal muscular atrophy. 分析师对该公司的评级是不同的,从"卖"到"超重",平均评级为"持有". Analysts have provided mixed ratings on the company, ranging from "sell" to "overweight," with an average rating of "Hold." 机构投资者最近也调整了其地位。 Institutional investors have also adjusted their positions in recent quarters.